ID   U2OS-GFP-STAT1/CSF-1R
AC   CVCL_D7E2
RX   Patent=US9683988;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.4688.
CC   Population: Caucasian.
CC   Characteristics: Expresses both GFP-STAT1 and CSF1R (Patent=US9683988).
CC   Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; 2433; CSF1R.
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; 11362; STAT1.
CC   Genetic integration: Method=Transfection/transduction; Gene=FPbase; R9NL8; eGFP (Note=Enhanced GFP).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D7E1 ! U2OS-GFP-STAT1
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   Patent=US9683988;
RA   Wang L.-L., Yang S.-Q., Long L., Xiao J.-H., Li S.;
RT   "Cell model and method for screening c-Fms kinase inhibitors.";
RL   Patent number US9683988, 20-Jun-2017.
//